Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
This Form 144 notice reports a proposed sale of 2,554 shares of Ventas, Inc. common stock through Northern Trust Securities with an aggregate market value of $179,435.36 and an approximate sale date of 10/01/2025. The filer acquired these shares as compensation shares on 01/25/2022 from Ventas, Inc.
The filing also discloses recent sales by the same person: 406 shares sold on 09/15/2025 for $28,418.94 and 2,040 shares sold on 09/30/2025 for $142,779.60. Outstanding shares reported on the form are 454,471,192, indicating the proposed sale is de minimis relative to total shares outstanding. The filer affirms no undisclosed material adverse information.
Ventas, Inc. (VTR) Form 144: This notice reports a proposed sale of 2,040 shares of Ventas common stock through Northern Trust Securities, Inc. on 09/30/2025 with an aggregate market value of $142,779.60. The shares were acquired as compensation shares on 01/25/2022 from Ventas, Inc. The filing also discloses that 406 shares were sold on 09/15/2025 by Peter J. Bulgarelli for $28,418.94. The filing includes the standard representation that the selling person does not possess undisclosed material adverse information and references Rule 10b5-1 plan adoption language, but no plan adoption date or signature block details are provided in the content supplied.
Peter J. Bulgarelli, an officer of Ventas, Inc. (VTR), reported a sale of common stock under a Rule 10b5-1 plan. The filing discloses that on 09/15/2025 Mr. Bulgarelli disposed of 406 shares at a weighted average price of $69.9974 per share. After the reported sale he beneficially owned 121,082 shares, held directly. The Form 4 notes the transaction was executed pursuant to a 10b5-1 trading plan entered into on February 20, 2025, and that the sale occurred in multiple transactions at prices ranging from $69.99 to $70.00. The form is signed by an attorney-in-fact on behalf of Mr. Bulgarelli on 09/17/2025.
Peter J. Bulgarelli, an officer of Ventas, Inc. (VTR), reported a sale of common stock under a Rule 10b5-1 plan. The filing discloses that on 09/15/2025 Mr. Bulgarelli disposed of 406 shares at a weighted average price of $69.9974 per share. After the reported sale he beneficially owned 121,082 shares, held directly. The Form 4 notes the transaction was executed pursuant to a 10b5-1 trading plan entered into on February 20, 2025, and that the sale occurred in multiple transactions at prices ranging from $69.99 to $70.00. The form is signed by an attorney-in-fact on behalf of Mr. Bulgarelli on 09/17/2025.
Ventas, Inc. (VTR) Form 144 shows a proposed sale of 406 common shares through Northern Trust Securities with an aggregate market value of $28,418.94. The shares are scheduled for sale on or about 09/15/2025 on the NYSE.
The filer acquired these shares as compensation shares from Ventas, Inc. on 01/25/2022. The filing reports 454,471,192 shares outstanding for the issuer and notes no securities sold in the past three months by the account. The notice includes the standard representation that the selling person is not aware of undisclosed material adverse information.
Ventas, Inc. (VTR) Form 144 shows a proposed sale of 406 common shares through Northern Trust Securities with an aggregate market value of $28,418.94. The shares are scheduled for sale on or about 09/15/2025 on the NYSE.
The filer acquired these shares as compensation shares from Ventas, Inc. on 01/25/2022. The filing reports 454,471,192 shares outstanding for the issuer and notes no securities sold in the past three months by the account. The notice includes the standard representation that the selling person is not aware of undisclosed material adverse information.
Debra A. Cafaro, Chairman and CEO of Ventas, Inc. (VTR), exercised 10,322 fully vested stock options on 09/02/2025 at an exercise price of $65.45 per share and simultaneously sold the 10,322 underlying shares under a Rule 10b5-1 trading plan entered 03/28/2024. The sales generated a weighted average sale price of $67.8031 per share. After these transactions the reporting person beneficially owns 1,145,695 shares and holds 681,287 unexercised options. The filing was signed on 09/04/2025 by an attorney-in-fact.
Ventas, Inc. (VTR) Form 144 notice reports a proposed sale of common stock by an insider and recent related sales. The filer indicates a broker-assisted sale of 10,322 shares valued at $699,863.18 to occur on 09/02/2025 on the NYSE. The filing states the shares were acquired the same day by exercise of employee stock options from Ventas, Inc.
The filing also discloses five common-stock sales by the same person during July–August 2025 totaling 31,990 shares with aggregate gross proceeds listed per sale (largest single prior sale: 14,753 shares for $967,822.54). Total shares outstanding is shown as 454,471,192, which provides context for the size of the proposed sale relative to the company.
Reporting person: Robert F. Probst, EVP and CFO of Ventas, Inc. (VTR). Transaction date: 08/04/2025; Form filed: 08/06/2025.
Actions: Probst exercised 29,691 fully vested stock options at an exercise price of $65.45 and sold 29,691 underlying shares pursuant to a Rule 10b5-1 trading plan entered on 02/19/2025. The shares were sold in multiple transactions at prices ranging $68.45–$68.5563 with a weighted average sale price of $68.4917.
Post-transaction position: Beneficial ownership reported as 168,364 shares held directly; 33,591 unexercised options remain (expiration 05/04/2026).